Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAdaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
27.98 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
3315525
Market Cap
4258.02M

Momentum Score

…

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
26.54
Low
28.27
High
52 Week Price Range
12.00
Low
27.34
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Adaptive Biotechnologies decodes the adaptive immune system using proprietary immune‑receptor sequencing and analytics to develop immune‑driven diagnostics and enable therapeutic discovery, including commercial products for minimal residual disease and immune profiling. Long-term growth may be supported by broader clinical adoption of MRD testing, platform licensing and partnerships, and accumulation of immune‑repertoire data that could enable new diagnostic and therapeutic applications.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
27.98
Dividend Yield
-
Revenue TTM
308.08M
Revenue Per Share
1.98
Gross Profit TTM
144.62M
Debt / Equity
1.28
ROE
-38.76%
Net Debt
210.09M
ROCE
-11.28%
Diluted EPS TTM
-0.43

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.46M -159.59M -225.30M -200.37M -207.30M
Minority interest -0.04M 0.10M 0.07M 0.18M -0.02M
Net income -59.50M -159.49M -225.25M -142.46M -205.61M
Selling general administrative 72.70M 72.81M 83.93M 88.53M 74.50M
Selling and marketing expenses 94.57M 84.76M 88.58M 95.60M 95.47M
Gross profit 205.62M 106.88M 94.72M 127.40M 105.04M
Reconciled depreciation 17.83M 19.26M 22.12M 20.92M 13.95M
Ebit -47.68M -148.01M -211.50M -200.19M -208.97M
Ebitda -29.85M -128.76M -189.27M -194.43M -207.27M
Depreciation and amortization 17.83M 19.26M 22.23M 5.75M 1.70M
Non operating income net other - - - 4.06M 1.67M
Operating income -57.12M -162.55M -227.03M -200.19M -208.97M
Other operating expenses 334.10M 341.51M 397.31M 385.49M 363.31M
Interest expense 11.78M 11.58M 13.80M 4.24M 1.67M
Tax provision - - - - 0.00M
Interest income 9.44M 14.53M 13.52M 4.06M 1.67M
Net interest income -2.33M 2.95M -0.85M -0.18M 1.67M
Income tax expense - - -0.05M -57.90M -1.69M
Total revenue 276.98M 178.96M 170.28M 185.31M 154.34M
Total operating expenses 262.74M 269.43M 321.76M 327.58M 314.01M
Cost of revenue 71.36M 72.08M 75.55M 57.91M 49.30M
Total other income expense net -2.33M 2.95M 1.73M -0.18M 1.67M
Net income from continuing ops -59.46M -159.59M -196.01M -200.37M -207.30M
Net income applicable to common shares - - - -200.19M -207.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 512.74M 539.38M 661.13M 856.62M 923.34M
Intangible assets 1.73M 3.42M 5.13M 6.83M 8.53M
Other current assets 13.02M 11.29M 10.37M 9.44M 13.02M
Total liab 287.74M 336.89M 352.86M 392.52M 319.24M
Total stockholder equity 218.79M 202.71M 308.40M 464.17M 603.99M
Other current liab 24.69M 24.68M 22.28M 28.36M 24.98M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1363.32M -1303.82M -1144.33M -919.08M -718.89M
Other liab - - - 183.96M 98.75M
Good will 118.97M 118.97M 118.97M 118.97M 118.97M
Other assets - - - 4.46M 3.01M
Cash 70.50M 47.92M 65.06M 90.03M 139.06M
Total current liabilities 89.92M 98.05M 88.02M 109.79M 113.81M
Current deferred revenue 45.19M 55.69M 48.63M 64.11M 80.46M
Net debt 210.09M 41.47M 164.37M 17.97M -27.32M
Short term debt 13.56M 10.24M 9.38M 9.23M 5.05M
Short long term debt total 280.58M 89.39M 229.43M 108.00M 111.74M
Other stockholder equity 1581.85M 1506.35M 1452.50M 1387.35M 1324.01M
Property plant equipment - - - 83.45M 85.26M
Total current assets 300.19M 283.75M 410.19M 562.15M 402.75M
Long term investments 13.23M 33.66M - 0.00M 217.15M
Net tangible assets - - - 338.37M 476.49M
Short term investments 156.49M 174.37M 281.34M 408.17M 214.00M
Net receivables 50.37M 41.73M 38.97M 40.06M 17.41M
Inventory 9.82M 8.44M 14.45M 14.45M 19.26M
Accounts payable 6.47M 7.26M 7.72M 8.08M 3.31M
Noncontrolling interest in consolidated entity - - - -0.07M 0.11M
Accumulated other comprehensive income 0.25M 0.17M 0.21M -4.12M -1.14M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -919.08M -718.89M
Non currrent assets other 1.21M 5.18M -1.54M 4.46M 3.01M
Non current assets total 212.55M 255.62M 250.95M 294.47M 520.60M
Capital lease obligations 79.15M 89.39M 98.77M 108.00M 111.74M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 40.91M 77.79M 28.90M 2.90M 242.96M
Change to liabilities - - - 7.11M 3.94M
Total cashflows from investing activities 37.95M 77.79M 129.65M 2.90M 181.21M
Total cash from financing activities 30.40M 0.24M 2.25M 132.26M 27.15M
Change to operating activities - - - -0.33M 9.53M
Net income -59.50M -159.59M -225.25M -200.37M -207.30M
Change in cash 22.37M -17.18M -24.97M -48.77M 15.63M
Begin period cash flow 50.82M 68.00M 90.03M 141.20M 125.57M
End period cash flow 73.18M 50.82M 65.06M 92.43M 141.20M
Total cash from operating activities -45.99M -95.21M -156.32M -183.94M -192.73M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 17.83M 19.26M 22.23M 20.92M 13.95M
Other cashflows from investing activities - - -0.00M - -
Change to inventory -1.00M 1.94M -2.84M 0.82M -5.20M
Change to account receivables -8.65M -3.74M 2.03M -22.65M -7.36M
Sale purchase of stock - - - 7.89M 26.72M
Other cashflows from financing activities 30.40M 0.24M 2.25M 124.38M 27.15M
Change to netincome - - - 56.44M 43.17M
Capital expenditures 2.96M 3.66M 10.70M 16.35M 61.75M
Change receivables - - - -22.65M -7.36M
Cash flows other operating - - - -46.96M -41.17M
Cash and cash equivalents changes - - - -48.77M 15.63M
Change in working capital -57.77M -17.45M -46.18M -71.55M -56.82M
Stock based compensation 51.48M 53.61M 62.91M 55.48M 43.25M
Other non cash items 19.80M 8.97M 92.88M 11.57M 6.95M
Free cash flow -48.95M -98.88M -167.02M -200.29M -254.47M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ADPT
Adaptive Biotechnologies Corp		 -
-%		 27.98 - - 13.82 27.67 13.05 -1.00
TMO
Thermo Fisher Scientific Inc		 17.82
2.63%		 694.76 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.91
1.73%		 230.25 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.45 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.31
1.23%		 24.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

1165 Eastlake Avenue East, Seattle, WA, United States, 98109

206 659 0067

https://www.adaptivebiotech.com

624

Name Title Year Born
Mr. Chad M. Robins M.B.A, M.B.A. Co-Founder, CEO & Chairman 1974
Ms. Julie Rubinstein Pres 1972
Dr. Harlan S. Robins Ph.D. Co-Founder & Chief Scientific Officer 1973
Mr. Nitin Sood Chief Commercial Officer of MRD NA
Mr. Christopher Carlson Ph.D. Founder NA
Mr. Tycho W. Peterson Chief Financial Officer NA
Dr. Mark Adams Ph.D. Chief Operating Officer 1967
Mr. Kyle Piskel Principal Accounting Officer 1984
Yi Zhou Chief Technical Officer NA
Karina Calzadilla VP of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…